{"id":17059,"date":"2025-01-22T14:53:15","date_gmt":"2025-01-22T07:53:15","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=17059"},"modified":"2025-01-22T14:53:15","modified_gmt":"2025-01-22T07:53:15","slug":"samsung-biologics-reports-fourth-quarter-and-fiscal-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=17059","title":{"rendered":"Samsung Biologics reports fourth quarter and fiscal year 2024 financial results"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2395686\/Samsung_Biologics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b> Recorded Q4&#8217;24 consolidated revenue of <span class=\"xn-money\">KRW 1.26 trillion<\/span><\/b><\/li>\n<li><b> Recorded FY&#8217;24 consolidated revenue of <span class=\"xn-money\">KRW 4.55 trillion<\/span><\/b><\/li>\n<li><b> Poised for further growth with expanded capacity and new service offerings<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">INCHEON, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Jan. 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>&#8220;2024 has been a year of steady progress for Samsung Biologics as we expanded collaboration with both pharma and biotech companies, supported by our focus on operational and quality excellence,&#8221; said <span class=\"xn-person\">John Rim<\/span>, CEO and President of Samsung Biologics. &#8220;We have been able to continue delivering on our commitments by investing in capacity, modality, and geographic expansion. We expect another year of growth through the opening of Plant 5, launch of ADC services, and continued investment in innovative technologies and sustainability. These efforts will enable us to better address the evolving needs of our clients at the right time.&#8221;<\/p>\n<p><b>FOURTH QUARTER &amp; FISCAL YEAR 2024 RESULTS<\/b><\/p>\n<p>In the fourth quarter of 2024, Samsung Biologics achieved a consolidated revenue of <span class=\"xn-money\">KRW 1.26 trillion<\/span> while operating profit stood at <span class=\"xn-money\">KRW 325.7 billion<\/span>. This growth was driven by the increased contribution from Plant 4 and full utilization of Plants 1 through 3.<\/p>\n<p>Full-year 2024 consolidated revenue was at <span class=\"xn-money\">KRW 4.55 trillion<\/span>, a 23% increase from <span class=\"xn-money\">KRW 3.69 trillion<\/span> in 2023. Operating profit increased by 19%, totaling to <span class=\"xn-money\">KRW 1.32 trillion<\/span>.<\/p>\n<p><b>[Consolidated Earnings, KRW billion]\u00a0<\/b><\/p>\n<div align=\"left\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnbrbrs prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q4&#8217;24<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q4&#8217;23<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Change<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">FY24<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">FY23<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Change<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prntac prncbts prnbrbrs prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Revenue<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,256.4<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,073.5<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+182.9<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+17.0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4,547.3<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3,694.6<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">852.7<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+23.1%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Operating <br \/>Profit<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">325.7<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">350.0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-24.3<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(-6.9%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,320.1<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,113.7<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">206.4<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+18.5%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EBITDA<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">476.5<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">491.9<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-154<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(-3.1%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,919.2<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,603.5<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">315.7<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+19.7%)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>On a standalone basis, Samsung Biologics recorded a revenue of <span class=\"xn-money\">KRW 3.50 trillion<\/span> and an operating profit of <span class=\"xn-money\">KRW 1.32 trillion<\/span> in 2024. In the fourth quarter of 2024 alone, the company posted a revenue of <span class=\"xn-money\">KRW 950.4 billion<\/span> and an operating profit of <span class=\"xn-money\">KRW 314.7 billion<\/span>.<\/p>\n<p>Samsung Biologics has served over 110 clients, including 17 of the worlds&#8217; top pharma companies, reinforcing its position as a trusted partner in the biopharmaceutical industry. These partnerships supported the company in surpassing a total contract value of <span class=\"xn-money\">USD 4.3 billion<\/span> in 2024, contributing to a cumulative contract value of <span class=\"xn-money\">USD 16.3 billion<\/span>. The company achieved 340 regulatory approvals as of <span class=\"xn-chron\">December 2024<\/span>, underscoring its commitment to quality and operational excellence.<\/p>\n<p><b>FISCAL YEAR 2025 OUTLOOK<\/b><\/p>\n<p>Full Plant 4 operations are expected to drive further revenue growth, while Plant 5 at Bio Campus II, scheduled to begin operations in <span class=\"xn-chron\">April 2025<\/span>, will expand the company&#8217;s total production capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the growing demand for biologics, which would increase total production capacity to 964,000 liters upon board approval.<\/p>\n<p>The dedicated ADC facility will address the growing need for ADC-based therapeutics by supporting the delivery of next-generation biomedicines. Additionally, the company&#8217;s innovative platforms S-HiCon\u2122, S-Tensify\u2122, S-AfuCHO\u2122, and S-OptiCharge\u2122 will offer clients enhanced flexibility, productivity, and quality for successful drug development.<\/p>\n<p>Samsung Biologics plans to further optimize operational efficiency and project timelines by investing in AI and digital transformation to automate systems and facilities. The company is also expanding its drug product (DP) capabilities, with a fully automated pre-filled syringe DP line projected to be CGMP-ready by 2027.<\/p>\n<p>Samsung Biologics continues to actively advance sustainability efforts. As a member of the Sustainable Markets Initiative&#8217;s Health Systems Task Force, the company is committed to developing practical guidelines for decarbonizing healthcare supply chains in collaboration with global leaders in public and private health sectors. By strengthening partnerships with suppliers and incorporating ESG principles into the value chain, Samsung Biologics aims to drive meaningful progress in its sustainability initiatives.<\/p>\n<p><b>About Samsung Biologics Co., Ltd.<\/b><\/p>\n<p>Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill\/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. Maximizing operational efficiency and expanding our capabilities in response to growing biomanufacturing demand, Samsung Biologics offers a combined 604 kL total capacity at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be operational in <span class=\"xn-chron\">April 2025<\/span>, adding 180 kL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and <span class=\"xn-location\">Europe<\/span>. We continue to upgrade our capabilities to accommodate our clients by investing in an ADC facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing services, operational excellence, and proven expertise.<\/p>\n<p><b>Samsung Biologics Contact<br \/><\/b><span class=\"xn-person\">Claire Kim<\/span>, Head of Global Marketing Communications<br \/><a href=\"mailto:cair.kim@samsung.com\" target=\"_blank\" rel=\"nofollow\">cair.kim@samsung.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2395686\/Samsung_Biologics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b> Recorded Q4&#8217;24 consolidated revenue of <span class=\"xn-money\">KRW 1.26 trillion<\/span><\/b><\/li>\n<li><b> Recorded FY&#8217;24 consolidated revenue of <span class=\"xn-money\">KRW 4.55 trillion<\/span><\/b><\/li>\n<li><b> Poised for further growth with expanded capacity and new service offerings<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">INCHEON, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Jan. 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>&#8220;2024 has been a year of steady progress for Samsung Biologics as we expanded collaboration with both pharma and biotech companies, supported by our focus on operational and quality excellence,&#8221; said <span class=\"xn-person\">John Rim<\/span>, CEO and President of Samsung Biologics. &#8220;We have been able to continue delivering on our commitments by investing in capacity, modality, and geographic expansion. We expect another year of growth through the opening of Plant 5, launch of ADC services, and continued investment in innovative technologies and sustainability. These efforts will enable us to better address the evolving needs of our clients at the right time.&#8221;<\/p>\n<p><b>FOURTH QUARTER &amp; FISCAL YEAR 2024 RESULTS<\/b><\/p>\n<p>In the fourth quarter of 2024, Samsung Biologics achieved a consolidated revenue of <span class=\"xn-money\">KRW 1.26 trillion<\/span> while operating profit stood at <span class=\"xn-money\">KRW 325.7 billion<\/span>. This growth was driven by the increased contribution from Plant 4 and full utilization of Plants 1 through 3.<\/p>\n<p>Full-year 2024 consolidated revenue was at <span class=\"xn-money\">KRW 4.55 trillion<\/span>, a 23% increase from <span class=\"xn-money\">KRW 3.69 trillion<\/span> in 2023. Operating profit increased by 19%, totaling to <span class=\"xn-money\">KRW 1.32 trillion<\/span>.<\/p>\n<p><b>[Consolidated Earnings, KRW billion]\u00a0<\/b><\/p>\n<div align=\"left\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnbrbrs prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q4&#8217;24<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q4&#8217;23<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Change<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">FY24<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">FY23<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Change<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prntac prncbts prnbrbrs prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Revenue<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,256.4<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,073.5<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+182.9<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+17.0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4,547.3<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3,694.6<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">852.7<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+23.1%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Operating <br \/>Profit<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">325.7<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">350.0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-24.3<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(-6.9%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,320.1<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,113.7<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">206.4<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+18.5%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EBITDA<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">476.5<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">491.9<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-154<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(-3.1%)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,919.2<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,603.5<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">315.7<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(+19.7%)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On a standalone basis, Samsung Biologics recorded a revenue of <span class=\"xn-money\">KRW 3.50 trillion<\/span> and an operating profit of <span class=\"xn-money\">KRW 1.32 trillion<\/span> in 2024. In the fourth quarter of 2024 alone, the company posted a revenue of <span class=\"xn-money\">KRW 950.4 billion<\/span> and an operating profit of <span class=\"xn-money\">KRW 314.7 billion<\/span>.<\/p>\n<p>Samsung Biologics has served over 110 clients, including 17 of the worlds&#8217; top pharma companies, reinforcing its position as a trusted partner in the biopharmaceutical industry. These partnerships supported the company in surpassing a total contract value of <span class=\"xn-money\">USD 4.3 billion<\/span> in 2024, contributing to a cumulative contract value of <span class=\"xn-money\">USD 16.3 billion<\/span>. The company achieved 340 regulatory approvals as of <span class=\"xn-chron\">December 2024<\/span>, underscoring its commitment to quality and operational excellence.<\/p>\n<p><b>FISCAL YEAR 2025 OUTLOOK<\/b><\/p>\n<p>Full Plant 4 operations are expected to drive further revenue growth, while Plant 5 at Bio Campus II, scheduled to begin operations in <span class=\"xn-chron\">April 2025<\/span>, will expand the company&#8217;s total production capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the growing demand for biologics, which would increase total production capacity to 964,000 liters upon board approval.<\/p>\n<p>The dedicated ADC facility will address the growing need for ADC-based therapeutics by supporting the delivery of next-generation biomedicines. Additionally, the company&#8217;s innovative platforms S-HiCon\u2122, S-Tensify\u2122, S-AfuCHO\u2122, and S-OptiCharge\u2122 will offer clients enhanced flexibility, productivity, and quality for successful drug development.<\/p>\n<p>Samsung Biologics plans to further optimize operational efficiency and project timelines by investing in AI and digital transformation to automate systems and facilities. The company is also expanding its drug product (DP) capabilities, with a fully automated pre-filled syringe DP line projected to be CGMP-ready by 2027.<\/p>\n<p>Samsung Biologics continues to actively advance sustainability efforts. As a member of the Sustainable Markets Initiative&#8217;s Health Systems Task Force, the company is committed to developing practical guidelines for decarbonizing healthcare supply chains in collaboration with global leaders in public and private health sectors. By strengthening partnerships with suppliers and incorporating ESG principles into the value chain, Samsung Biologics aims to drive meaningful progress in its sustainability initiatives.<\/p>\n<p><b>About Samsung Biologics Co., Ltd.<\/b><\/p>\n<p>Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill\/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. Maximizing operational efficiency and expanding our capabilities in response to growing biomanufacturing demand, Samsung Biologics offers a combined 604 kL total capacity at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be operational in <span class=\"xn-chron\">April 2025<\/span>, adding 180 kL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and <span class=\"xn-location\">Europe<\/span>. We continue to upgrade our capabilities to accommodate our clients by investing in an ADC facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing services, operational excellence, and proven expertise.<\/p>\n<p><b>Samsung Biologics Contact<br \/><\/b><span class=\"xn-person\">Claire Kim<\/span>, Head of Global Marketing Communications<br \/><a href=\"mailto:cair.kim@samsung.com\" target=\"_blank\" rel=\"nofollow\">cair.kim@samsung.com<\/a>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-17059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17059"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17059\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}